Mirati’s Adagrasib Challenger Fails To Differentiate Itself From Amgen’s Lumakras
Executive Summary
While adagrasib showed decent efficacy in its pivotal study in NSCLC, some analysts said its inability to outperform Amgen’s Lumakras and its safety profile leave little room for differentiation.
You may also be interested in...
ESMO: Mirati’s Adagrasib Appears To Maintain CRC Edge In KRAS Race
The company is reporting strong ORR, durability and PFS at ESMO in heavily pretreated colorectal cancer, an indication where Amgen’s Lumakras has struggled.
Oncternal And SpringWorks Among Early ASCO Winners And Losers
While the big pharma names dominate the ASCO cancer congress, it is also a chance to shine for emerging small-to-medium biopharma companies.